Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Announces Earnings Results

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) posted its quarterly earnings data on Wednesday. The company reported $0.01 earnings per share for the quarter, FiscalAI reports. The business had revenue of $3.57 million for the quarter.

Hong Kong Pharma Digital Technology Stock Performance

Shares of NASDAQ HKPD opened at $0.63 on Friday. The stock’s fifty day simple moving average is $0.74 and its 200 day simple moving average is $0.99. Hong Kong Pharma Digital Technology has a 52-week low of $0.58 and a 52-week high of $2.76.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Hong Kong Pharma Digital Technology has an average rating of “Sell”.

Hedge Funds Weigh In On Hong Kong Pharma Digital Technology

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new position in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned approximately 0.39% of Hong Kong Pharma Digital Technology at the end of the most recent quarter.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.